ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,1047
-0,50%
Bitcoin
66.843,36
2,46%
Brent Oil
83,76
0,67%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. BioMarin Pharmaceutical Inc (BMRN)

  7. BioMarin Pharmaceutical Inc (BMRN) Notícias

BMRN

BioMarin Pharmaceutical (BMRN)

BioMarin Pharmaceutical Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:BMRN
DataHoraFonteTítuloCódigoCompanhia
14/05/202418:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BMRNBioMarin Pharmaceutical Inc
13/05/202416:57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
10/05/202411:11Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
08/05/202409:00PR Newswire (US)BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NVNASDAQ:BMRNBioMarin Pharmaceutical Inc
04/05/202417:00PR Newswire (US)New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual MeetingNASDAQ:BMRNBioMarin Pharmaceutical Inc
24/04/202417:03PR Newswire (US)BioMarin Reports Record Financial Results for the First Quarter 2024NASDAQ:BMRNBioMarin Pharmaceutical Inc
10/04/202409:00PR Newswire (US)BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ETNASDAQ:BMRNBioMarin Pharmaceutical Inc
12/03/202409:30PR Newswire (US)New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics MeetingNASDAQ:BMRNBioMarin Pharmaceutical Inc
07/03/202410:30PR Newswire (US)BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial OfficerNASDAQ:BMRNBioMarin Pharmaceutical Inc
01/03/202411:00PR Newswire (US)BioMarin Scheduled to Participate in March Investor ConferencesNASDAQ:BMRNBioMarin Pharmaceutical Inc
26/02/202415:34Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:BMRNBioMarin Pharmaceutical Inc
22/02/202418:03PR Newswire (US)BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024NASDAQ:BMRNBioMarin Pharmaceutical Inc
12/02/202417:24Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
09/02/202419:46Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:BMRNBioMarin Pharmaceutical Inc
08/02/202410:00PR Newswire (US)BioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4:30pm ETNASDAQ:BMRNBioMarin Pharmaceutical Inc
06/02/202410:30PR Newswire (US)BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders (EAHAD) CongressNASDAQ:BMRNBioMarin Pharmaceutical Inc
26/01/202413:49Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:BMRNBioMarin Pharmaceutical Inc
03/01/202410:00PR Newswire (US)BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT / 1:30 pm ET, in San Francisco, CANASDAQ:BMRNBioMarin Pharmaceutical Inc
28/12/202315:15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
20/12/202318:05PR Newswire (US)BioMarin Announces Governance Enhancements and Value Creation InitiativesNASDAQ:BMRNBioMarin Pharmaceutical Inc
28/11/202310:30PR Newswire (US)BioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in GermanyNASDAQ:BMRNBioMarin Pharmaceutical Inc
02/11/202317:09Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BMRNBioMarin Pharmaceutical Inc
02/11/202315:53Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BMRNBioMarin Pharmaceutical Inc
01/11/202317:05PR Newswire (US)BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over YearNASDAQ:BMRNBioMarin Pharmaceutical Inc
01/11/202317:02PR Newswire (US)BioMarin Announces Retirement of Jean-Jacques Bienaimé; Appoints Alexander Hardy President and Chief Executive OfficerNASDAQ:BMRNBioMarin Pharmaceutical Inc
20/10/202317:54Dow Jones NewsBioMarin Pharmaceutical's Achondroplasia Treatment Gets FDA Approval for All Pediatric PatientsNASDAQ:BMRNBioMarin Pharmaceutical Inc
20/10/202317:05PR Newswire (US)U.S. Food and Drug Administration Approves BioMarin's VOXZOGO® (vosoritide) for Children Under 5 Years with AchondroplasiaNASDAQ:BMRNBioMarin Pharmaceutical Inc
17/10/202309:30PR Newswire (US)BioMarin to Host Third-Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, November 1, at 4:30pm ETNASDAQ:BMRNBioMarin Pharmaceutical Inc
21/09/202311:00PR Newswire (US)BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) MeetingNASDAQ:BMRNBioMarin Pharmaceutical Inc
15/09/202310:29PR Newswire (US)BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO® (vosoritide) to Treat Children Aged 4 Months and Older with AchondroplasiaNASDAQ:BMRNBioMarin Pharmaceutical Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:BMRN

Seu Histórico Recente

COIN
APEIUSD
APE INU
NASDAQ
DEACW
Diamond Eagle Acquisition
LSE
0LHW
Us Gold
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados